NICE National Institute for Health and Care Excellence

**Date and Time:** 29th July, 2013 1000 - 1600

**Minutes:**

**Transfusion: Blood Transfusion**

**Guideline Development Group Meeting 2**

**Place:** NCGC, 180 Great Portland Street, London, W1W 5QZ

**Present:**

**GDG**

| | |
|---|---|
| Mike Murphy | (Chair) MM |
| David Blackwell | (Transfusion Practitioner) DB |
| Graham Donald | (Patient Member) GD |
| Kenneth Halligan | (Patient Member) KH |
| Karen Madgwick | (Transfusion Lab Scientist) KM |
| Mary Marsden | (Transfusion Nurse) MM |
| Robert Morris | (Surgeon) |
| Helen New | (Consultant Paediatrician) |
| Susan Robinson | (Consultant Haematologist) |
| Shubha Allard | (Consultant Haematologist) |

**NCGC**

| | |
|---|---|
| Jennifer Hill | (Guideline lead) JH |
| Carlos Sharpin | (Joint Head of Information Scientists) CS |
| Smita Padhi | (Senior Research Fellow) SP |
| Sharangini Rajesh | (Research Fellow) SR |
| Sophia Winterbourne | (Health Economist) SW |
| Tamara Diaz | (Project Manager) TD |

**Apologies**

| | |
|---|---|
| Dafydd Thomas | (Consultant Anaesthetist) DT |
| Timothy Walsh | (Anaesthetist/Intensivist)TW |

**In attendance:**

| | |
|---|---|
| Grace Marsden | (Senior Health Economist) GM |
| Joanna Ashe | (Senior Information Scientist) JA |

| | | |
|---|---|---|
| **NICE Staff:** | Claire Ruiz | (Guideline Commissioning Manager) |
| | | |

## Notes

1. Introductions and apologies. MM welcomed the group to the second meeting of this GDG. Apologies were noted from DT and TW. HN, due to a previous commitment would leave the meeting at the lunch break.

2. Declarations of Interests (DOIs). The Chair asked all GDG members to declare any relevant conflicts of interest since GDG 1. The following DOIs were noted from MM: he is an employee of National Health Service Blood and Transplant (NHS BT) the only blood supplier for blood components in England, he has written various articles on many aspects of Blood Transfusion and he has done extensive work in the area of electronic transfusion systems. The following DOIs were noted from HN: her husband is a consultant for a biotechnology company, ReNeuron PLC, currently developing stem cell therapies for diagnostic and therapeutic applications. Additionally, HN is the lead on a writing group for the new British Committee for Standards in Haematology (BCSH) guidelines on neonatal and paediatric transfusion in preparation, is a member of the Serious Hazards of Transfusion (SHOT) working expert group and steering group, and a member of the scientific committee of Network for Advances of Transfusion Alternatives (NATA). SA mentioned that she has been a member of several transfusion related guideline development groups. None of these DOIs required further action for items on the day's agenda.

3. The draft NICE minutes of GDG 1. The Minutes of GDG 1, the Joint Trauma/Transfusion Training day, were agreed as a true and accurate account of the meeting.

4. Review protocol. Oral/intraveneous iron and Erythropoietin. The review protocol was presented by CS. The GDG discussed and formally agreed on the review protocol.

5. Evidence review. Oral/Intraveneous iron and Erythropoietin. The clinical evidence was presented by SR. The GDG discussed draft recommendations.

6. Health economics. Oral/Intraveneous iron and Erythropoietin. SW presented the economic evidence. The GDG discussed the evidence and the draft recommendations.

7. Prioritisation of Topics for Health Economic Analysis. SW presented the topics identified by stakeholders as potential candidates for health economic modelling and discussed the criteria that the GDG should use for assessing these topics for prioritisation.

8. Review protocols. SP led the GDG in discussions on review protocols for the following topics: Monitoring for acute reactions, electronic patient identification systems, tranexamic acid and cell salvage.

## Date, time and venue of the next meeting

9. GDG 3: 3 September 2013, 1000 – 1600 in the Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.